Oppenheimer Reaffirms Outperform Rating for Odyssey Therapeutics (NASDAQ:ODTX)

Odyssey Therapeutics (NASDAQ:ODTX)‘s stock had its “outperform” rating reissued by equities researchers at Oppenheimer in a note issued to investors on Thursday,Benzinga reports. They presently have a $40.00 price target on the stock. Oppenheimer’s price objective points to a potential upside of 117.04% from the stock’s current price.

A number of other equities analysts have also commented on ODTX. Wedbush began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective on the stock. Wall Street Zen raised Odyssey Therapeutics to a “hold” rating in a research note on Saturday, May 16th. Cantor Fitzgerald began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating on the stock. TD Cowen began coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating on the stock. Finally, Zacks Research raised Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Odyssey Therapeutics Stock Down 0.3%

Shares of Odyssey Therapeutics stock traded down $0.05 during midday trading on Thursday, reaching $18.43. The company had a trading volume of 158,404 shares, compared to its average volume of 323,311. Odyssey Therapeutics has a fifty-two week low of $15.35 and a fifty-two week high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings data on Wednesday, June 17th. The company reported $999.00 EPS for the quarter, topping analysts’ consensus estimates of ($1.31) by $1,000.31.

Insiders Place Their Bets

In other Odyssey Therapeutics news, Director Nan (Ln) Li bought 1,111,111 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the acquisition, the director owned 3,333,516 shares in the company, valued at $60,003,288. This trade represents a 50.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Tpg Gp A, Llc bought 1,388,889 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $18.00 per share, with a total value of $25,000,002.00. Following the completion of the acquisition, the insider owned 3,690,146 shares of the company’s stock, valued at $66,422,628. This represents a 60.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 4,183,777 shares of company stock valued at $75,319,986 in the last 90 days.